ADAM8 and neoplasm: In summary, new bifunctional ADAM8 inhibitors selectiveover ADAM10and several MMPs involved in tumor progression have been developed.Following a dimerization strategy, a first bifunctional derivativehas been synthesized starting from an arylsulfonamido-based hydroxamicacid, JG26, previously reported as an ADAM17 inhibitor.